Novasep builds €30m plant
Enlarge image


Novasep builds €30m plant

11.10.2012 - French chromatography specialist Novasep will create the world's largest chromatography plant for the pharmaceutical industry.

French bio-chromatography provider Novasep S.A. is set to build the world’s largest chromatography plant in Europe at its Mourenx site, for purification of pharmaceuticals. The company, which combined its technologies in large scale chromatography with German stationary phase provider instrAction two years ago, said the plant will be operational and validated within 18 months. Both the development of an advanced purification process and the plant expansion within the challenging timescale are results of the sharp increase in the projected demand for a large volume, highly purified API. New analyses from Frost & Sullivan predict the monoclonal antibody market in Europe to grow from US$19bn in 2011 to US$42.4bn in 2018 alone.

The €30m investment follows two other significant global investments in 2012: the opening of a new 2,000sqm facility in Shanghai and a €3m investment to expand the Highly Potent API (HPAPI) manufacturing capabilities in Le Mans. "Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third, and largest global plant expansion in 2012," said Patrick Glaser, President and CEO of Novasep. The investment was supported by contributions of local authorities of Lacq, the General Council of Pyrénées Atlantiques, the Regional Council of Aquitaine, the Economic Development Bureau, DIRECCTE Aquitaine, the Prefecture of Pyrénées Atlantiques, the Total Group, and OSEO, France's innovation agency.



24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD46.1%
  • CELLECTIS (F)30.70 EUR32.8%


  • EPIGENOMICS (D)1.87 EUR-58.6%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5266.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR255.9%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 25.11.2015